{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n In lung adenocarcinoma (LUAD), BFSP2‑AS1 has been identified as one of eight long non‑coding RNAs forming a prognostic signature that predicts patient survival and risk (1). This signature not only stratifies patients based on clinical outcomes but is also strongly associated with variations in tumor immune infiltration, including alterations in the abundance of multiple immune cell populations and the expression of MHC molecules. Such associations suggest that BFSP2‑AS1 may be involved in modulating the tumor immune microenvironment and could serve as a promising target for the development of novel LUAD therapies (1)."}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ""}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Yan Chen, Xiuxiu Zhang, Jinze Li, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Immune-related eight-lncRNA signature for improving prognosis prediction of lung adenocarcinoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Clin Lab Anal (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/jcla.24018"}], "href": "https://doi.org/10.1002/jcla.24018"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "34550610"}], "href": "https://pubmed.ncbi.nlm.nih.gov/34550610"}]}]}]}